HANGZHOU, Sept. 11 (Xinhua) -- A recent study led by Chinese scientists has identified a gene defect -- PLD4 deficiency -- that can cause systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease affecting millions of patients worldwide. The findings, published in Nature on Wednesday, provide crucial insights for future targeted therapies.
The research was conducted by a team from Liangzhu Laboratory at Zhejiang University, with Liu Zhihong, Yu Xiaomin, and Zhou Qing as co-corresponding authors.
SLE is characterized by high heterogeneity, varying widely in both clinical manifestations and genetic background, which has long complicated understanding of its pathogenesis.
Using whole-exome sequencing, the team identified recessive mutations in the PLD4 gene in five SLE patients with lupus nephritis. The PLD4 gene is expressed in key immune cells, including dendritic cells, B cells, and monocytes. The deficiency of PLD4 was shown to trigger sustained inflammation and autoimmune activation.
Further validation in mouse models demonstrated that baricitinib, a JAK inhibitor, effectively alleviated symptoms such as weight loss, autoantibody production, and tissue inflammation in mice with the PLD4 defect.
This breakthrough suggests that baricitinib may offer a targeted therapy for SLE patients with PLD4 mutations, paving the way for genotype-based personalized medicine in lupus care. ■
Coffee plants enter harvest season in Baoshan, China's Yunnan
2025 China Golden Rooster and Hundred Flowers Film Festival concludes in Xiamen
Lakes nurture ecological wetland in Gobi Desert, NW China's Gansu
Students engage in cultural heritage education at Xixia Imperial Tombs archaeological site park
点击右上角
微信好友
朋友圈

请使用浏览器分享功能进行分享
